

## SWOG Cancer Research Network at ASCO 2026

Calendar of oral, rapid oral, and poster presentations on SWOG-led or co-led work

Full information on ASCO 2026 SWOG-associated work: [swog.org/media/26051](https://swog.org/media/26051)



Study #	Abstract Title, Link, & 1 <sup>st</sup> Author or Speaker	Session Title, Track, Location, Date, & Time (CDT)
	<b>Saturday, May 30, 2026</b>	
C/S80702	Lycopene and survival in patients with stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702 <a href="https://meetings.asco.org/abstracts-presentations/262239">https://meetings.asco.org/abstracts-presentations/262239</a> First Author: <b>S Lee</b>	Session: Gastrointestinal Cancer—Colorectal and Anal Abstract 3630 Poster board 397 <b>Saturday, May 30, 9 am - 12 pm CT, Hall A</b>
S2433	S2433: Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma <a href="https://meetings.asco.org/abstracts-presentations/267747">https://meetings.asco.org/abstracts-presentations/267747</a> First Author: <b>RA Safyan</b>	Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Abstract TPS4264 Poster Board: 234b <b>Saturday, May 30, 9 am - 12 pm CT, Hall A</b>
Multiple	Participation of Older Adults (≥65 Years) in SWOG Cancer Clinical Trials <a href="https://meetings.asco.org/abstracts-presentations/263125">https://meetings.asco.org/abstracts-presentations/263125</a> First Author: <b>J Parajuli</b>	Session: Care Delivery/Models of Care Abstract 1543 Poster Board: 267 <b>Saturday, May 30, 9 am - 12 pm CT, Hall A</b>
S1609	Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Lung and/or Liver Metastases (NCI/SWOG S1609) <a href="https://meetings.asco.org/abstracts-presentations/257763">https://meetings.asco.org/abstracts-presentations/257763</a> First Author: <b>M Othus</b>	Session: Developmental Therapeutics—Immunotherapy Abstract 2633 Poster Board: 423 <b>Saturday, May 30, 1:30 - 4:30 pm CT, Hall A</b>
S1714	Post-Treatment Recovery Patterns among Patients with Early-Stage Cancer who Develop Taxane-Induced Peripheral Neuropathy (TIPN): SWOG S1714 (NCT03939481) <a href="https://meetings.asco.org/abstracts-presentations/268251">https://meetings.asco.org/abstracts-presentations/268251</a> First Author: <b>M Trivedi</b> Presenter: <b>DL Hertz</b>	Session: Symptom Science and Palliative Care Abstract 12117 Poster Board: 100 <b>Saturday, May 30, 1:30 - 4:30 pm CT, Hall A</b>
Multiple (18 SWOG trials)	A Risk Prediction Model for Severe, Life-Threatening, and Fatal Treatment-Related Toxicity <a href="https://meetings.asco.org/abstracts-presentations/258344">https://meetings.asco.org/abstracts-presentations/258344</a> First Author: <b>JM Unger</b>	Session: Symptom Science and Palliative Care Abstract 12143 Poster Board: 126 <b>Saturday, May 30, 1:30 - 4:30 pm CT, Hall A</b>
S0221	Role of pretreatment vitamin D insufficiency in racial disparity in taxane-induced peripheral neuropathy: Results from the SWOG S0221 trial <a href="https://meetings.asco.org/abstracts-presentations/258292">https://meetings.asco.org/abstracts-presentations/258292</a> First Author: <b>N Nguyen-Hoang</b>	Session: Symptom Science and Palliative Care Abstract 12136 Poster Board: 119 <b>Saturday, May 30, 1:30 - 4:30 pm CT, Hall A</b>
S2013	Immune Checkpoint Inhibitor (ICI) Toxicity in a Large Prospective Cohort of Patients with Solid Tumors: The I-CHECKIT Study (SWOG S2013) <a href="https://meetings.asco.org/abstracts-presentations/257765">https://meetings.asco.org/abstracts-presentations/257765</a> First Author: <b>K Gunturu</b>	Session: Developmental Therapeutics—Immunotherapy Abstract 2640 Poster Board: 430 <b>Saturday, May 30, 1:30 - 4:30 pm CT, Hall A</b>

S1823	<p>First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer</p> <p><a href="https://meetings.asco.org/abstracts-presentations/260571">https://meetings.asco.org/abstracts-presentations/260571</a></p> <p>First Author: <b>L Nappi</b></p>	<p>Session: Genitourinary Cancer—Prostate, Testicular, and Penile</p> <p>Oral Abstract # LBA5003</p> <p><b>Saturday, May 30, 3-6 pm CT, Hall D1 &amp; Live Stream</b></p> <p>Presentation: 3:36 - 3:48 pm CT</p>
<b>Sunday, May 31, 2026</b>		
S1714	<p>Vitamin D insufficiency and risk of taxane-induced peripheral neuropathy: Results from SWOG S1714</p> <p><a href="https://meetings.asco.org/abstracts-presentations/258211">https://meetings.asco.org/abstracts-presentations/258211</a></p> <p>First Author: <b>N Nguyen-Hoang</b></p>	<p>Session: Symptom Science and Palliative Care</p> <p>Rapid Oral Abstract 12012</p> <p><b>Sunday, May 31, 8 - 9:30 am CT, Room S403</b></p> <p>Presentation: 8:30 - 8:36 am CT</p>
S2107	<p>SWOG S2107: randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAFV600E metastatic colorectal cancer (mCRC)</p> <p><a href="https://meetings.asco.org/abstracts-presentations/260545">https://meetings.asco.org/abstracts-presentations/260545</a></p> <p>First Author: <b>V Morris</b></p>	<p>Session: Gastrointestinal Cancer—Colorectal and Anal</p> <p>Oral Abstract 3504</p> <p><b>Sunday, May 31, 8 – 11 am CT, Hall D2 &amp; Live Stream</b></p> <p>Presentation: 9:12 - 9:24 am CT</p>
S1609	<p>DART (NCI/SWOG S1609): Comprehensive Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers</p> <p><a href="https://meetings.asco.org/abstracts-presentations/258018">https://meetings.asco.org/abstracts-presentations/258018</a></p> <p>First Author: <b>SP Patel</b></p>	<p>Session: Developmental Therapeutics—Immunotherapy</p> <p>Oral Abstract 2502</p> <p><b>Sunday, May 31, 8 – 11 am CT, Arie Crown Theater &amp; Live Stream</b></p> <p>Presentation: 8:24 – 8:36 am CT</p>
S2414	<p>SWOG S2414 (INSIGHT): A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early-Stage Non-Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting</p> <p><a href="https://meetings.asco.org/abstracts-presentations/266722">https://meetings.asco.org/abstracts-presentations/266722</a></p> <p>First Author: <b>J Cetnar</b></p>	<p>Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers</p> <p>Abstract TPS8131</p> <p>Poster Board: 601a</p> <p><b>Sunday, May 31, 9 am - 12 pm CT, Hall A</b></p>
S1800E	<p>Lung-MAP S1800E: A randomized phase II/III study of docetaxel and ramucirumab with or without cemiplimab for patients previously treated with platinum-based chemotherapy &amp; immunotherapy for stage IV or recurrent non-small cell lung cancer</p> <p><a href="https://meetings.asco.org/abstracts-presentations/266698">https://meetings.asco.org/abstracts-presentations/266698</a></p> <p>First Author: <b>S Waqar</b></p>	<p>Session: Lung Cancer—Non-Small Cell Metastatic</p> <p>Abstract TPS8669</p> <p>Poster Board: 454a</p> <p><b>Sunday, May 31, 9 am - 12 pm CT, Hall A</b></p>
S1900G	<p>A Randomized Phase II Study of Capmatinib plus Osimertinib with or without Ramucirumab in Patients with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study S1900G)</p> <p><a href="https://meetings.asco.org/abstracts-presentations/266695">https://meetings.asco.org/abstracts-presentations/266695</a></p> <p>First Author: <b>S Goldberg</b></p>	<p>Session: Lung Cancer—Non-Small Cell Metastatic</p> <p>Abstract TPS8677</p> <p>Poster Board: 458a</p> <p><b>Sunday, May 31, 9 am - 12 pm CT, Hall A</b></p>
S1900J	<p>A Phase II study of amivantamab hyaluronidase in MET amplification-positive stage IV or recurrent non-small cell lung cancer (Lung-MAP Sub-Study)</p> <p><a href="https://meetings.asco.org/abstracts-presentations/266701">https://meetings.asco.org/abstracts-presentations/266701</a></p> <p>First Author: <b>C Rolfo</b></p>	<p>Session: Lung Cancer—Non-Small Cell Metastatic</p> <p>Abstract TPS8680</p> <p>Poster Board: 459b</p> <p><b>Sunday, May 31, 9 am - 12 pm CT, Hall A</b></p>

S1400A, S1400I, S1400F, S1800A	Immune-Related Adverse Event Severity and Clinical Outcomes with Immune Checkpoint Inhibitor Immunotherapy in Participants with Non-Small Cell Lung Cancer: Analysis of the Lung MAP sub-studies S1400A, S1400I, S1400F, and S1800A <a href="https://meetings.asco.org/abstracts-presentations/265964">https://meetings.asco.org/abstracts-presentations/265964</a> First Author: <b>D Tseng</b>	Session: Lung Cancer—Non-Small Cell Metastatic Abstract 8572 Poster Board: 362 <b>Sunday, May 31, 9 am - 12 pm CT, Hall A</b>
S1216	Correlation of baseline testosterone (T) level with survival outcomes in patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study <a href="https://meetings.asco.org/abstracts-presentations/260774">https://meetings.asco.org/abstracts-presentations/260774</a> First Author: <b>G Gebrael</b>	Session: Genitourinary Cancer—Prostate, Testicular, and Penile Abstract 5096 Poster Board: 191 <b>Sunday, May 31, 9 am - 12 pm CT, Hall A</b>
CCTG-PR.26	TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924) <a href="https://meetings.asco.org/abstracts-presentations/266930">https://meetings.asco.org/abstracts-presentations/266930</a> First Author: <b>M Ong</b>	Poster Session: Genitourinary Cancer—Prostate, Testicular, and Penile Abstract TPS5149 Poster Board: 235a <b>Sunday, May 31, 9 am - 12 pm CT, Hall A</b>
<b>Monday, June 1, 2026</b>		
S1912CD	Baseline Financial and Credit Status of Participants Enrolled in SWOG S1912CD <a href="https://meetings.asco.org/abstracts-presentations/259675">https://meetings.asco.org/abstracts-presentations/259675</a> First Author: <b>V Shankaran</b>	Session: Quality Care/Health Services Research Abstract 11049 Poster Board: 32 <b>Monday, June 1, 9 am - 12 pm CT, Hall A</b>
Multiple (6 SWOG trials)	The Association of Baseline Fatigue and Severe Cancer Treatment Toxicity Persists by Comorbid Conditions: A Pooled Analysis <a href="https://meetings.asco.org/abstracts-presentations/259698">https://meetings.asco.org/abstracts-presentations/259698</a> First Author: <b>M Caplan</b>	Session: Quality Care/Health Services Research Abstract 11036 Poster Board: 19 <b>Monday, June 1, 9 am - 12 pm CT, Hall A</b>
Multiple	Prevalence and Trends in Rural Patient Enrollment in SWOG Cancer Clinical Trials, 1992-2022 <a href="https://meetings.asco.org/abstracts-presentations/259725">https://meetings.asco.org/abstracts-presentations/259725</a> First Author: <b>I Okado</b>	Session: Quality Care/Health Services Research Abstract 11068 Poster Board: 51 <b>Monday, June 1, 9 am - 12 pm CT, Hall A</b>
S8814	External Validation of the locked ArteraAI Breast MMAI model for Prognosis and Chemotherapy Benefit Prediction in Postmenopausal, Node-Positive, Hormone Receptor-Positive Breast Cancer Patients: Analysis of SWOG S8814 <a href="https://meetings.asco.org/abstracts-presentations/260430">https://meetings.asco.org/abstracts-presentations/260430</a> First Author: <b>CW Speers</b>	Session: Clinical Science Symposium - From Data to Decisions: Applying Artificial Intelligence for Smarter, More Accessible Cancer Care Oral Abstract 107 <b>Monday, June 1, 9:45 - 11:15 am CT, Hall D1 &amp; Live Stream</b> Presentation: 10:09 – 10:21 am CT
S2001	Randomized Phase II Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 (gBRCA1/2) Mutations: SWOG S2001 <a href="https://meetings.asco.org/abstracts-presentations/259304">https://meetings.asco.org/abstracts-presentations/259304</a> First Author: <b>V Chung</b>	Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Rapid Oral Abstract 4012 <b>Monday, June 1, 1:15 - 2:45 pm CT, Hall D2 &amp; Live Stream</b> Presentation: 1:45 - 1:51 pm CT

S2010	Associations between self-efficacy and symptom burden in young women with breast cancer initiating endocrine therapy (ET) on SWOG S2010 <a href="https://meetings.asco.org/abstracts-presentations/265781">https://meetings.asco.org/abstracts-presentations/265781</a> First Author: <b>NL Henry</b>	Session: Breast Cancer—Local/Regional/Adjuvant Abstract 521 Poster board 6 <b>Monday, June 1, 1:30 - 4:30 pm CT, Hall A</b>
-------	---	--